Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation

Takako Miyamura, Kousuke Chayama, Tomoaki Wada, Kazunari Yamaguchi, Nobuko Yamashita, Toshiaki Ishida, Kana Washio, Naoto Morishita, Akira Manki, Megumi Oda, Tsuneo Morishima

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

CAEBV is a high mortality and morbidity disease with lifethreatening complications. Nevertheless, the treatment regimens for CAEBV have not yet been established. Although some reports have described CAEBV therapy involving treatments such as antiviral drugs, immunomodulatory agents, and immunochemotherapy, none of these treatments have been demonstrated to be effective. The only treatment reported to be effective is allogeneic SCT. However, the complications of SCT are severe, so treatment results have been poor. Recently, immunotherapy has been devised, but this is still in the developmental stage. In this report, two cases of CAEBV in which allogeneic SCT was performed soon after diagnosis are reported. In both cases, a high EBV genome titer in the peripheral blood was detected at onset. After SCT, the EBV genome titer decreased as CTL activity gradually increased. This fact suggested that not only high-dose chemotherapy as a preconditioning treatment of SCT but also increased CTL activity which could eliminate virus-infected cells might be effective, although additional cases should be studied in order to establish effective treatments.

Original languageEnglish
Pages (from-to)588-592
Number of pages5
JournalPediatric Transplantation
Volume12
Issue number5
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Epstein-Barr Virus Infections
Homologous Transplantation
Cytotoxic T-Lymphocytes
Bone Marrow Transplantation
Human Herpesvirus 4
Therapeutics
Genome
Immunotherapy
Antiviral Agents
Viruses
Morbidity
Drug Therapy
Mortality

Keywords

  • Barr virus infection
  • Bone marrow transplantation
  • Chronic active Epstein
  • Cytotoxic T lymphocyte

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation. / Miyamura, Takako; Chayama, Kousuke; Wada, Tomoaki; Yamaguchi, Kazunari; Yamashita, Nobuko; Ishida, Toshiaki; Washio, Kana; Morishita, Naoto; Manki, Akira; Oda, Megumi; Morishima, Tsuneo.

In: Pediatric Transplantation, Vol. 12, No. 5, 08.2008, p. 588-592.

Research output: Contribution to journalArticle

Miyamura, Takako ; Chayama, Kousuke ; Wada, Tomoaki ; Yamaguchi, Kazunari ; Yamashita, Nobuko ; Ishida, Toshiaki ; Washio, Kana ; Morishita, Naoto ; Manki, Akira ; Oda, Megumi ; Morishima, Tsuneo. / Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation. In: Pediatric Transplantation. 2008 ; Vol. 12, No. 5. pp. 588-592.
@article{7adcf32e330a4678b9f64402fac7f0ed,
title = "Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation",
abstract = "CAEBV is a high mortality and morbidity disease with lifethreatening complications. Nevertheless, the treatment regimens for CAEBV have not yet been established. Although some reports have described CAEBV therapy involving treatments such as antiviral drugs, immunomodulatory agents, and immunochemotherapy, none of these treatments have been demonstrated to be effective. The only treatment reported to be effective is allogeneic SCT. However, the complications of SCT are severe, so treatment results have been poor. Recently, immunotherapy has been devised, but this is still in the developmental stage. In this report, two cases of CAEBV in which allogeneic SCT was performed soon after diagnosis are reported. In both cases, a high EBV genome titer in the peripheral blood was detected at onset. After SCT, the EBV genome titer decreased as CTL activity gradually increased. This fact suggested that not only high-dose chemotherapy as a preconditioning treatment of SCT but also increased CTL activity which could eliminate virus-infected cells might be effective, although additional cases should be studied in order to establish effective treatments.",
keywords = "Barr virus infection, Bone marrow transplantation, Chronic active Epstein, Cytotoxic T lymphocyte",
author = "Takako Miyamura and Kousuke Chayama and Tomoaki Wada and Kazunari Yamaguchi and Nobuko Yamashita and Toshiaki Ishida and Kana Washio and Naoto Morishita and Akira Manki and Megumi Oda and Tsuneo Morishima",
year = "2008",
month = "8",
doi = "10.1111/j.1399-3046.2007.00873.x",
language = "English",
volume = "12",
pages = "588--592",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation

AU - Miyamura, Takako

AU - Chayama, Kousuke

AU - Wada, Tomoaki

AU - Yamaguchi, Kazunari

AU - Yamashita, Nobuko

AU - Ishida, Toshiaki

AU - Washio, Kana

AU - Morishita, Naoto

AU - Manki, Akira

AU - Oda, Megumi

AU - Morishima, Tsuneo

PY - 2008/8

Y1 - 2008/8

N2 - CAEBV is a high mortality and morbidity disease with lifethreatening complications. Nevertheless, the treatment regimens for CAEBV have not yet been established. Although some reports have described CAEBV therapy involving treatments such as antiviral drugs, immunomodulatory agents, and immunochemotherapy, none of these treatments have been demonstrated to be effective. The only treatment reported to be effective is allogeneic SCT. However, the complications of SCT are severe, so treatment results have been poor. Recently, immunotherapy has been devised, but this is still in the developmental stage. In this report, two cases of CAEBV in which allogeneic SCT was performed soon after diagnosis are reported. In both cases, a high EBV genome titer in the peripheral blood was detected at onset. After SCT, the EBV genome titer decreased as CTL activity gradually increased. This fact suggested that not only high-dose chemotherapy as a preconditioning treatment of SCT but also increased CTL activity which could eliminate virus-infected cells might be effective, although additional cases should be studied in order to establish effective treatments.

AB - CAEBV is a high mortality and morbidity disease with lifethreatening complications. Nevertheless, the treatment regimens for CAEBV have not yet been established. Although some reports have described CAEBV therapy involving treatments such as antiviral drugs, immunomodulatory agents, and immunochemotherapy, none of these treatments have been demonstrated to be effective. The only treatment reported to be effective is allogeneic SCT. However, the complications of SCT are severe, so treatment results have been poor. Recently, immunotherapy has been devised, but this is still in the developmental stage. In this report, two cases of CAEBV in which allogeneic SCT was performed soon after diagnosis are reported. In both cases, a high EBV genome titer in the peripheral blood was detected at onset. After SCT, the EBV genome titer decreased as CTL activity gradually increased. This fact suggested that not only high-dose chemotherapy as a preconditioning treatment of SCT but also increased CTL activity which could eliminate virus-infected cells might be effective, although additional cases should be studied in order to establish effective treatments.

KW - Barr virus infection

KW - Bone marrow transplantation

KW - Chronic active Epstein

KW - Cytotoxic T lymphocyte

UR - http://www.scopus.com/inward/record.url?scp=55949097010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949097010&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2007.00873.x

DO - 10.1111/j.1399-3046.2007.00873.x

M3 - Article

VL - 12

SP - 588

EP - 592

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 5

ER -